|
May 13
|
INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript
|
|
May 12
|
INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations
|
|
May 9
|
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
|
|
May 7
|
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
|
|
Apr 30
|
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
|
|
Apr 29
|
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
Apr 26
|
INmune Bio Independent Director Acquires 80% More Stock
|
|
Apr 25
|
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Apr 23
|
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
|
|
Apr 22
|
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
|
|
Apr 8
|
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
|
|
Apr 1
|
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
|
|
Mar 31
|
INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 29
|
INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements
|
|
Mar 28
|
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
|
|
Mar 26
|
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
|
|
Mar 13
|
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
|
|
Mar 5
|
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
|
|
Feb 6
|
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
|
|
Feb 4
|
Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company
|